Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead (NASDAQ:ARWR)

分组1 - Arrowhead Pharmaceuticals received its first approval for plozasiran, an siRNA therapy for Familial Chylomicronemia Syndrome (FCS) in adults, in November 2025 [1] - This approval marks a significant milestone for Arrowhead, which has one of the longest-tailed pipelines in the pre-commercial stage, as it has now crossed a major regulatory hurdle [1] - The company has yet to start commercializing the approved therapy [1] 分组2 - Mr. Arunangshu Das is developing Tranzoro Investments to assist US investors in understanding Indian markets and vice versa [1] - The focus will be on liquid and well-known India-focused ETFs and ADRs for US investors, while covering a wide range of US equities, ETFs, and REITs for Indian investors [1] - Mr. Das is characterized as an income and growth-focused investor [1]